Biotech Strategy Blog
Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy
-
Promising Novel Targets or More of the Same?
-
The Therapeutic Index Dilemma
-
20 key lessons learned from AstraZeneca at AACR
-
Taking on the Guardian of the Genome
-
Breaking through barriers
-
When good news isn’t quite what it seems
-
The Organoid Revolution: FDA’s new stance and what it means for biopharma
-
Bridging the gap – where ADCs and protein degraders are really heading
-
Divvying up the ASCO spoils
-
Critical Analysis of the Emerging Trispecific Landscape